Reviewing ligand-based rational drug design: The search for an ATP synthase inhibitor

International Journal of Molecular Sciences

Volumn 12, Issue 8, 2011, Pages 5304-5318

  Lee, Chia Hsien ^a   Huang, Hsuan Cheng ^b   Juan, Hsueh Fen ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

ATP synthase ligands; Pharmacophore; Quantitative structure activity relationships

Indexed keywords

ADENOSINE TRIPHOSPHATASE INHIBITOR; ASTELTOXIN; AUROVERTIN B; BATHOPHENANTHROLINE; CITREOVIRIDIN; ENTEROSTATIN; LIGAND; MEPACRINE MUSTARD; PICEATANNOL; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE INHIBITOR; RESVERATROL; UNCLASSIFIED DRUG; ENZYME INHIBITOR; PROTEIN BINDING; PROTEIN SUBUNIT; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE;

BINDING SITE; CANCER THERAPY; COMPUTER AIDED DESIGN; DRUG DESIGN; DRUG PROTEIN BINDING; DRUG STRUCTURE; HYDROGEN BOND; INTERMETHOD COMPARISON; LIGAND BINDING; MOLECULAR DOCKING; PHARMACOPHORE; PREDICTION; PROCESS OPTIMIZATION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; SCORING SYSTEM; SURFACE PROPERTY; THREE DIMENSIONAL IMAGING; VALIDATION PROCESS; ANTAGONISTS AND INHIBITORS; CHEMICAL PHENOMENA; CHEMICAL STRUCTURE; CHEMISTRY; HUMAN; METABOLISM; PROTEIN SUBUNIT;

BINDING SITES; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; LIGANDS; MITOCHONDRIAL PROTON-TRANSLOCATING ATPASES; MODELS, MOLECULAR; PROTEIN BINDING; PROTEIN SUBUNITS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 80052160108     PISSN: None     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms12085304     Document Type: Review

References (66)

1. Sneader, W. Drug Discovery: A History; John Wiley & Sons, Ltd.: Chichester, UK, 2005.
2. Drews, J. Drug discovery: a historical perspective. Science 2000, 287, 1960-1964.
3. Butcher, E.C.; Berg, E.L.; Kunkel, E.J. Systems biology in drug discovery. Nat. Biotechnol. 2004, 22, 1253-1259.
4. Chen, Y.P.; Chen, F. Identifying targets for drug discovery using bioinformatics. Expert Opin. Ther. Targets 2008, 12, 383-389.
5. Engel, T. Basic overview of chemoinformatics. J. Chem. Inf. Model. 2006, 46, 2267-2277.
6. Moon, J.B.; Howe, W.J. Computer design of bioactive molecules: a method for receptor-based de novo ligand design. Proteins 1991, 11, 314-328.
7. Sleno, L.; Emili, A. Proteomic methods for drug target discovery. Curr. Opin. Chem. Biol. 2008, 12, 46-54.
8. Cavasotto, C.N.; Phatak, S.S. Homology modeling in drug discovery: current trends and applications. Drug Discov. Today 2009, 14, 676-683.
9. Ivanov, A.S.; Veselovsky, A.V.; Dubanov, A.V.; Skvortsov, V.S. Bioinformatics platform development: from gene to lead compound. Methods Mol. Biol. 2006, 316, 389-431.
10. Chen, Z.; Li, H.L.; Zhang, Q.J.; Bao, X.G.; Yu, K.Q.; Luo, X.M.; Zhu, W.L.; Jiang, H.L. Pharmacophore-based virtual screening versus docking-based virtual screening: a benchmark comparison against eight targets. Acta. Pharmacol. Sin. 2009, 30, 1694-1708.
11. Wang, Y.; Shaikh, S.A.; Tajkhorshid, E. Exploring transmembrane diffusion pathways with molecular dynamics. Physiology 2010, 25, 142-154
12. Bemporad, D.; Luttmann, C.; Essex, J.W. Behaviour of small solutes and large drugs in a lipid bilayer from computer simulations. Biochim. Biophys. Acta 2005, 1718, 1-21.
13. Tintori, C.; Manetti, F.; Botta, M. Pharmacophoric models and 3D QSAR studies of the adenosine receptor ligands. Curr. Top. Med. Chem. 2010, 10, 1019-1035.
14. Vogt, M.; Bajorath, J. Predicting the performance of fingerprint similarity searching. Methods Mol. Biol. 2011, 672, 159-173.
15. Langer, T.; Hoffmann, R.D. Virtual screening: an effective tool for lead structure discovery? Curr. Pharm. Des. 2001, 7, 509-527.
16. Scior, T.; Medina-Franco, J.L.; Do, Q.T.; Martínez-Mayorga, K.; Yunes Rojas, J.A.; Bernard, P. How to recognize and workaround pitfalls in QSAR studies: a critical review. Curr. Med. Chem. 2009, 16, 4297-4313.
17. Ehrlich, P. Ueber den jetzigen Stand der Chemotherapie. Ber. Dtsch. Chem. Ges. 1909, 42, 17-47.
18. van Drie, J.H. Pharmacophore discovery-lessons learned. Curr. Pharm. Des. 2003, 9, 1649-1664.
19. Wolber, G.; Seidel, T.; Bendix, F.; Langer, T. Molecule-pharmacophore superpositioning and pattern matching in computational drug design. Drug Discov. Today 2008, 13, 23-19.
20. Yang, S.Y. Pharmacophore modeling and applications in drug discovery: challenges and recent advances. Drug Discov. Today 2010, 15, 444-450.
21. Kubinyi, H. Success Stories of Computer-Aided Design. In Computer Applications in Pharmaceutical Research and Development; Ekins, S., Wang, B., Eds.; Wiley-Interscience: Hoboken, NJ, USA, 2006; pp. 377-424.
22. McNaught, A.D.; Wilkinson, A. Compendium of Chemical Terminology-IUPAC Recommendations, 2nd ed.; Blackwell Science: Hoboken, NJ, USA, 1997.
23. Rankovic, Z.; Morphy, R. Lead Generation Approaches in Drug Discovery; John Wiley & Sons, Inc.: Hoboken, NJ, USA, 2011; pp. 86-90.
24. Chen, I.J.; Foloppe, N. Is conformational sampling of drug-like molecules a solved problem? Drug Dev. Res. 2011, 72, 85-94.
25. Güner, O.F. History and evolution of the pharmacophore concept in computer-aided drug design. Curr. Top. Med. Chem. 2002, 2, 1321-1332.
26. Mustata, G.; Follis, A.V.; Hammoudeh, D.I.; Metallo, S.J.; Wang, H.; Prochownik, E.V.; Lazo, J.S.; Bahar, I. Discovery of novel Myc-Max heterodimer disruptors with a three-dimensional pharmacophore model. J. Med. Chem. 2009, 52, 1247-1250.
27. Petersen, R.K.; Christensen, K.B.; Assimopoulou, A.N.; Fretté, X.; Papageorgiou, V.P.; Kristiansen, K.; Kouskoumvekaki, I. Pharmacophore-driven identification of PPARγ agonists from natural sources. J. Comput. Aided Mol. Des. 2011, 25, 107-116.
28. Barroso, I.; Gurnell, M.; Crowley, V.E.; Agostini, M.; Schwabe, J.W.; Soos, M.A.; Maslen, G.L.; Williams, T.D.; Lewis, H.; Schafer, A.J. Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 1999, 402, 880-883.
29. Lyne, P.D.; Kenny, P.W.; Cosgrove, D.A.; Deng, C.; Zabludoff, S.; Wendoloski, J.J.; Ashwell, S. Identification of compounds with nanomolar binding affinity for checkpoint kinase-1 using knowledge-based virtual screening. J. Med. Chem. 2004, 47, 1962-1968.
30. Peach, M.L.; Nicklaus, M.C. Combining docking with pharmacophore filtering for improved virtual screening. J. Cheminform. 2009, 1, 6:1-6:15.
31. Esposito, E.X.; Hopfinger, A.J.; Madura, J.D. Methods for applying the quantitative structureactivity relationship paradigm. Methods. Mol. Biol. 2004, 275, 131-214.
32. Perkins, R.; Fang, H.; Tong, W.; Welsh, W.J. Quantitative structure-activity relationship methods: perspectives on drug discovery and toxicology. Environ. Toxicol. Chem. 2003, 22, 1666-1679.
33. Du, Q.S.; Huang, R.B.; Chou, K.C. Recent advances in QSAR and their applications in predicting the activities of chemical molecules, peptides and proteins for drug design. Curr. Protein Pept. Sci. 2008, 9, 248-260.
34. Bradbury, S.P. Quantitative structure-activity relationships and ecological risk assessment: an overview of predictive aquatic toxicology research. Toxicol. Lett. 1995, 79, 229-237.
35. Martinez-Mayorga, K.; Medina-Franco, J.L. Chemoinformatics-applications in food chemistry. Adv. Food. Nutr. Res. 2009, 58, 33-56.
36. Myint, K.Z.; Xie, X.Q. Recent advances in fragment-based QSAR and multi-dimensional QSAR methods. Int. J. Mol. Sci. 2010, 11, 3846-3866.
37. De Melo, E.B. Multivariate SAR/QSAR of 3-aryl-4-hydroxyquinolin-2(1H)-one derivatives as type I fatty acid synthase (FAS) inhibitors. Eur. J. Med. Chem. 2010, 45, 5817-5826.
38. Zhou, T.; Shi, Q.; Chen, C.H.; Zhu, H.; Huang, L.; Ho, P.; Lee, K.H. Anti-AIDS agents 79. Design, synthesis, molecular modeling and structure-activity relationships of novel dicamphanoyl-2',2'-dimethyldihydropyranochromone (DCP) analogs as potent anti-HIV agents. Bioorg. Med. Chem. 2010, 18, 6678-6689.
39. Karolidis, D.A.; Agatonovic-Kustrin, S.; Morton, D.W. Artificial neural network (ANN) based modelling for D1 like and D2 like dopamine receptor affinity and selectivity. Med. Chem. 2010, 6, 259-270.
40. Chen, C.; Yang, J. MI-QSAR models for prediction of corneal permeability of organic compounds. Acta Pharmacol. Sin. 2006, 27, 193-204.
41. Tropsha, A.; Zheng, W. Identification of the descriptor pharmacophores using variable selection QSAR: applications to database mining. Curr. Pharm. Des. 2001, 7, 599-612.
42. Cramer, R.D., III; Patterson, D.E.; D. Bunce, J.D. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J. Am. Chem. Soc. 1988, 110, 5959-5967.
43. Klebe, G.; Abraham, U.; Mietzner, T. Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J. Med. Chem. 1994, 37, 4130-4146.
44. Turner, D.B.; Willett, P. The EVA spectral descriptor. Eur. J. Med. Chem. 2000, 35, 367-375.
45. Katritzky, A.R.; Gordeeva, E.V. Traditional topological indices vs. electronic, geometrical, and combined molecular descriptors in QSAR/QSPR research. J. Chem. Inf. Comput. Sci. 1993, 33, 835-857.
46. Whitley, D.C.; Ford, M.G.; Livingstone, D.J. Unsupervised forward selection: a method for eliminating redundant variables. J. Chem. Inf. Comput. Sci. 2000, 40, 1160-1168.
47. Chen, H.; Zhou, J.; Xie, G. PARM: a genetic evolved algorithm to predict bioactivity. J. Chem. Inf. Comput. Sci. 1998, 38, 243-250.
48. Rogers, D.; Hopfinger, A.J. Application of genetic function approximation to quantitative structure-activity relationships and quantitative structure-property relationships. J. Chem. Inf. Comput. Sci. 1994, 34, 854-866.
49. Xue, L.; Godden, J.W.; Bajorath, J. Evaluation of descriptors and mini-fingerprints for the identification of molecules with similar activity. J. Chem. Inf. Comput. Sci. 2000, 40, 1227-1234.
50. Wikel, J.H.; Dow, E.R. The use of neural networks for variable selection in QSAR. Bioorg. Med. Chem. Lett. 1993, 3, 645-651.
51. Itskowitz, P.; Tropsha, A. k nearest neighbors QSAR modeling as a variational problem: theory and applications. J. Chem. Inf. Model. 2005, 45, 777-785.
52. Jain, A.N.; Koile, K.; Chapman, D. Compass: Predicting biological activities from molecular surface properties. performance comparisons on a steroid benchmark. J. Med. Chem. 1994, 37, 2315-2327.
53. Shahlaei, M.; Fassihi, A.; Saghaie, L. Application of PC-ANN and PC-LS-SVM in QSAR of CCR1 antagonist compounds: a comparative study. Eur. J. Med. Chem. 2010, 45, 1572-1582.
54. Silverman, B.D.; Platt, D.E. Comparative molecular moment analysis (CoMMA): 3D-QSAR without molecular superposition. J. Med. Chem. 1996, 39, 2129-2140.
55. Kurogi, Y.; Güner, O.F. Pharmacophore modeling and three-dimensional database searching for drug design using catalyst. Curr. Med. Chem. 2001, 8, 1035-1055.
56. Verma, J.; Khedkar, V.M.; Coutinho, E.C. 3D-QSAR in drug design-a review. Curr. Top. Med. Chem. 2010, 10, 95-115.
57. Cramer, R.D., III; Bunce, J.D.; Patterson, D.E.; Frank, I.E. Crossvalidation, bootstrapping, and partial least squares compared with multiple regression in conventional QSAR studies. Quant. Struct.-Act. Relat. 1988, 7, 18-25.
58. Tropsha, A.; Gramatica, P.; Gombar, V.K. The importance of being earnest: validation is the absolute essential for successful application and interpretation of QSPR models. QSAR Comb. Sci. 2003, 22, 69-77.
59. Consonni, V.; Ballabio, D.; Todeschini, R. Comments on the definition of the Q2 parameter for QSAR validation. J. Chem. Inf. Model. 2009, 49, 1669-1678.
60. Saghaie, L.; Shahlaei, M.; Fassihi, A.; Madadkar-Sobhani, A.; Gholivand, M.B.; Pourhossein, A. QSAR analysis for some diaryl-substituted pyrazoles as CCR2 inhibitors by GA-stepwise MLR. Chem. Biol. Drug. Des. 2011, 77, 75-85.
61. Obiol-Pardo, C.; Gomis-Tena, J.; Sanz, F.; Saiz, J.; Pastor, M. A multiscale simulation system for the prediction of drug-induced cardiotoxicity. J. Chem. Inf. Model. 2011, 51, 483-492.
62. Huang, T.C.; Chang, H.Y.; Hsu, C.H.; Kuo, W.H.; Chang, K.J.; Juan, H.F. Targeting therapy for breast carcinoma by ATP synthase inhibitor aurovertin B. J. Proteome Res. 2008, 7, 1433-1444.
63. Sayers, E.W.; Barrett, T.; Benson, D.A.; Bolton, E.; Bryant, S.H.; Canese, K.; Chetvernin, V.; Church, D.M.; Dicuccio, M.; Federhen, S.; et al. Database resources of the national center for biotechnology information. Nucleic Acids Res. 2010, 38, D5-D16.
64. Hong, S.; Pedersen, P.L. ATP synthase and the actions of inhibitors utilized to study its roles in human health, disease, and other scientific areas. Microbiol. Mol. Biol. Rev. 2008, 72, 590-641.
65. Barnum, D.; Greene, J.; Smellie, A.; Sprague, P. Identification of common functional configurations among molecules. J. Chem. Inf. Comput. Sci. 1996, 36, 563-571.
66. Smellie, A.; Teig, S.L.; Towbin, P. Poling: promoting conformational variation. J. Comp. Chem. 1995, 16, 171-187.